Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is a biopharmaceutical company with a positive outlook due to their strong track record of producing effective antibodies, with their lead product PEMGARDA showing 84% protective efficacy in their CANOPY trial and their next-generation antibody VYD2311 targeting a much larger population for potential approval by 2027. The company has also received emergency use authorization for PEMGARDA in immunocompromised individuals and has a strong pipeline of potential candidates targeting other viral diseases. Based on current data and management's comments, we believe Invivyd's COVID-19 approaches are superior to mRNA vaccines and could potentially provide longer protection with a single dose. Our valuation, based on a risk-adjusted discounted cash flow model, yields a total firm value of approximately $3 billion or a $10 price target. Risks to our outlook include standard risks in the biopharmaceutical industry, as well as competition, commercialization, reimbursement, and pricing risks for their product candidates.

Bears say

Invivyd is facing a potential roadblock with the termination of its EUA for PEMGARDA by the FDA, as well as the twelve-month transition window for its approval. However, management remains confident in the data for its next-generation antibody candidates and is actively in dialogue to potentially pursue a BLA pathway. The upcoming DECLARATION trial readout for VYD2311 is seen as the main value driver for the company, with management highlighting its strong protection, durability, and low reactogenicity. While payer and policy feedback appear positive, broad access may depend on ACIP/CMS dynamics and the pricing of the expensive prophylactic mAb.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.